Baculovirus Expression System Market Fast-Tracking Therapies: The Baculovirus Expression System Market - A Key to Speeding Up Drug Development

Baculovirus Expression System Market worth $660.97 Mn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Baculovirus Expression System Market- (By Product Type (Baculovirus, Expression Vector, Reagents, Others), By Application (Therapeutics, Vaccines, Protein Purification, Others), By End User (Biopharmaceutical Companies, Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Baculovirus Expression System Market is valued at US$ 351.48 Mn in 2022, and it is expected to reach US$ 660.97 Mn by 2031, with a CAGR of 7.35% during the forecast period of 2024-2031.

Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/2227

The Baculovirus Expression System: A Powerful Tool for Protein Production
The Baculovirus Expression System is a robust and versatile biotechnological tool widely used in molecular biology and biotechnology for recombinant protein production. It leverages baculoviruses, a family of insect-infecting viruses, to express and produce specific target proteins. This technology offers significant advantages for research on viruses and various other biotech applications.

The increasing prevalence of chronic illnesses like infectious diseases, autoimmune disorders, and cancer fuels the demand for innovative therapeutic proteins and vaccines. The Baculovirus Expression System plays a crucial role in this area, enabling the production of several effective biological drugs, including gene therapy vectors and monoclonal antibodies.

The global biologics and biosimilars market is experiencing significant growth due to the development and licensing of more biologic medications, such as monoclonal antibodies, recombinant proteins, and cell and gene therapies, for treating chronic illnesses. Notably, the Baculovirus Expression System effectively produces many licensed and pipeline biologic drugs.

However, the Sf21 insect cell line, derived from the Sf9 parent cells, is gaining popularity. Sf21 cells facilitate more regular post-translational modifications, like glycosylation, in recombinant proteins. This enhanced capability makes them highly effective for protein expression, yielding high-quality proteins with varying degrees of complexity.

List of Prominent Players in the baculovirus expression system market:

• Thermo Fisher Scientific
• Vivopure
• Creative Biogene
• Absolute Antibody
• Rockland Immunochemicals
• Protein Technologies Inc.
• Proteogenix
• Virovek
• Merck KGaA
• Takara Bio
• Agilent Technologies
• Oxford Expression Technologies
• Promega Corporation
• Qiagen N.V.
• Bio-Rad Laboratories
• New England Biolabs
• Genscript Biotech Corporation
• Syngene International Limited
• Sartorius AG
• Aragen Bioscience

Market Dynamics:

Drivers-
The growing demand for baculovirus expression systems is fueled because the adeno-associated virus (AAV) and other gene therapy vectors are increasingly produced using the baculovirus expression system. Creating therapeutic gene-carrying rAAV vectors in large quantities is now feasible. Several recently licensed gene therapy drugs, along with robust clinical pipelines, will increase demand for viral vectors, which in turn will spur widespread adoption of the baculovirus platform. Using baculovirus expression for the cost-effective and time-saving production of gene treatments is attracting significant investments from industry leaders.

Challenges:
The prime challenge is high cost, a shortage of competent individuals, and a lack of norms and protocol because the risks of contamination by adventitious viruses and prions are increased when using live baculoviruses and media containing serum. This increases the chances of human health and the likelihood of product rejection, leading to the waste of valuable reagents and bioprocessing components. Biosafety measures, such as serum-free systems, can be used to reduce the likelihood of adverse events. However, the high-yield expression of several proteins is still challenging.

This complicating factor may limit the usefulness of some kinds of protein drugs. The pandemic of COVID-19 has shown the importance of having a fast, scalable manufacturing platform for vaccines and treatments. With the baculovirus-insect cell technology, vaccine antigens may be rapidly produced to counteract new pandemic risks.

Regional Trends:
The North American baculovirus expression system market is anticipated to register a major market share in revenue. It is projected to grow at a high CAGR in the near future due to the rising production and approval of biologics such as monoclonal antibodies, recombinant proteins, and cell and gene therapies for treating chronic diseases.

In addition, the baculovirus expression system market is expanding because of the rising expenditure in life science R&D by government agencies, academic institutions, and biopharmaceutical corporations to quicken the pace of drug development. Besides, Europe had a considerable share in the market due to the region's growing pharmaceutical and biotechnology sectors, which have increased their demand for recombinant proteins.

Curious About This Latest Version of The Report? Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/2227

Recent Developments:

• In March 2022, ProteoGenix declared the introduction of the XtenCHOTM Transient Expression System. The novel proprietary expression host based on mammalian cells obtained up to ten times greater yields with reduced manual labour in comparison to established alternatives; this was due to the optimized metabolism and enhanced stability of the plasmid. With the new CHO host, recombinant protein synthesis was intended to be simplified, and early-phase drug screening accelerated.

Segmentation of Baculovirus Expression System Market-
By Product Type-
• Baculovirus
• Expression Vector
• Reagents
• Others

By Application-
• Therapeutics
• Vaccines
• Protein Purification
• Others

By End User-
• Biopharmaceutical Companies
• Research Institutes
• Others

By Region-
North America-
• The US
• Canada
• Mexico

Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-
• Brazil
• Argentina
• Rest of Latin America

Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/report/baculovirus-expression-system-market/2227

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.